Printer Friendly

ELECTROPHYSIOLOGY TRANSFORMING ARTRIAL FIBRILLATION TREATMENT.

Millennium Research Group (MRG), Waltham, Mass., a global authority on medical technology market intelligence, has recently published its latest issue of Cardiovascular Industry Quarterly (CardioIQ), a quarterly publication highlighting the most recent trends and events in the cardiovascular industry. According to CardioIQ, electrophysiology (EP) catheter ablation is emerging as the preferred treatment for atrial fibrillation (AF), a common form of cardiac arrhythmia that affects almost 3 million people in the US.

Technological innovation in EP catheter ablation, coupled with strong clinical outcomes, have resulted in increased physician recognition of EP catheter ablation as a viable option for treating AF patients, facilitating very rapid US procedure and market growth. Advances in EP catheter technology have enabled more accurate diagnoses and targeted therapies, while strong clinical outcomes have convinced physicians of the safety and efficacy of EP catheter ablation for AF treatment. The combination of increased physician recognition and benefits from innovative technological advancement will drive the market through 2012.

MRG also publishes quarterly publications on the orthopedics (OrthoIQ), aesthetics (AestheticsIQ), endoscopy, urology & gynecology (EndoIQ), and imaging and IT markets (ImagingIQ).

About Millennium Research Group

Millennium Research Group (http://www.mrg.net/), a Decision Resources, Inc. company (http://www.decisionresources.com/), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized consulting services.

For more information, visit http://www.mrg.net or call 416/364-7776, ext. 101.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Date:Sep 1, 2008
Words:251
Previous Article:ORBUSNEICH ADDS SAPHHIRE NC CORONARY DILATATION CATHETER.
Next Article:RIVERAING WINS COMPUTER-AIDED DETECTION CONTRACT.
Topics:


Related Articles
FDA APPROVES CARDIMA'S BALLOON OCCLUSION GUIDING CATHETER
CARDIMA REPORTS 105% INCREASE IN REVENUES.
CARDIMA REPORTS 55% INCREASE IN REVENUES FOR FIRST QTR.
EP MEDSYSTEMS SUBMITS ORIGINAL PMA ON ALERT SYSTEM WITH FDA.
EP MEDSYSTEMS REPORTS INCREASED SALES FOR 4TH QTR.
PRORYTHM REPORTS USE OF STEERABLE HIFU ABALATION SYSTEM.
ATRIAL FIBRILLATION PROCEDURES TO GROW OVER 25% ANNUALLLY.
April records series of device industry mergers.
RF ABLATION CATHETER ISOLATES VEINS IN ARTRIAL FIBRILLATION.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters